Avalyn Pharma Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
No qualifying bottom-picking events since 2020.
Top Wall Street analysts upgraded LEA, BAH, TRV, and CGNX stocks, with higher price targets. See what analysts think of other stocks on rating page.
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Outperform rating and announces Price Target of $51.
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on AVLN stock.
Guggenheim analyst Seamus Fernandez initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Buy rating and announces Price Target of $80.
Morgan Stanley analyst Judah Frommer initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Overweight rating and announces Price Target of $53.
Wall Street Week Ahead: track key market events, earnings (CRM, DELL), GDP/PCE, IPOs, dividends and volatility. Read here for more details.
Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced an upcoming poster
The company's poster presentations are listed below and will be presented in the following session: Thematic Poster Session B39 – Breath and Burden: Diffuse Lung Diseases and Daily Life, Monday, May 18, 2026, 11:30 a.m.
Four IPOs priced this past week, led by three sizable biotechs. They were joined by 11 blank check listings.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Four IPOs priced this past week, featuring nuclear tech, critical materials, real estate, and convenience stores. Read more here.
One IPO priced this past week, joined by two SPACs, and twelve deals joined the pipeline. Read more here.
Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AVLN | -3.55% | — | — | — |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -6.52% | — | — | — |